Therapeuticsmd Inc (TXMD) 4.53 $TXMD
TherapeuticsMD to Hold Second Quarter 2014 Financial Results Conference Call and Webcast on August 6
Business Wire - Fri Aug 01, 6:00AM CDT
TherapeuticsMD (NYSE MKT:TXMD), a women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss its second quarter financial and business results Wednesday, August 6. The conference call and webcast will take place at 4:30 p.m. EDT and will be hosted by Robert Finizio, Chief Executive Officer, and Dan Cartwright, Chief Financial Officer.
TherapeuticsMD plans to issue USD40m shares in public offering
M2 - Wed Jul 30, 6:37AM CDT
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) said on Tuesday that it intends to start its public offering of USD40m shares of its common stock.
TherapeuticsMD Announces Pricing of Offering of Common Stock
Business Wire - Wed Jul 30, 6:01AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the "Company"
announced today the pricing of an underwritten public offering of approximately 8.6 million shares of its common stock, offered at a price of $4.67 per share. The gross proceeds to the Company from this offering are expected to be approximately $40.0 million, before deducting underwriting discounts, commissions and other estimated offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 1.3 million additional shares of its common stock. The offering is expected to close on or about August 4, 2014, subject to the satisfaction of customary closing conditions.
TherapeuticsMD Announces $40 Million Offering of Common Stock
Business Wire - Tue Jul 29, 3:13PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company" today announced the launch of an underwritten public offering of $40 million of shares of its common stock. All of the shares in the offering are to be sold by the Company. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional $6 million of shares of its common stock.
Technical Coverage on Pharma Stocks -- GlaxoSmithKline, TherapeuticsMD, AstraZeneca, Zogenix, and Novartis
PR Newswire - Tue Jul 22, 8:10AM CDT
On Monday, July 21, 2014, the NASDAQ Composite ended at 4,424.70, down 0.17%, the Dow Jones Industrial Average declined 0.28%, to finish the day at 17,051.73, and the S&P 500 closed at 1,973.63, down 0.23%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 707.91, down 0.39%, while the index has advanced 6.22% in the previous three months. Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), TherapeuticsMD Inc. (NYSE MKT: TXMD), AstraZeneca PLC (NYSE: AZN), Zogenix Inc. (NASDAQ: ZGNX), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at:
TherapeuticsMD Investor Update; BrokerBank Securities, Inc. Offers Insight on Long-Term Uncertainty Amid Short-Term Catalysts
PR Newswire - Tue Jul 15, 1:30PM CDT
According to BCC Research, the global market for women's health therapeutics is expected to reach $22.5 billion in 2018. Due to a variety of factors, such as an aging worldwide population, an increasing awareness among patients and physicians, the introduction of new therapies into the market, and the overall disease pattern and treatment differences between men and women, this market is expected to grow at a CAGR of 3.5% over the next five years.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Jul 13, 6:30AM CDT
It was a rough week on Wall Street, with the market moving lower, but there were plenty of stocks still moving higher. Let's take a closer look at five of this past week's biggest scorchers. Company July 11 Weekly Gain ...
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD)
at The Street - Thu Jul 10, 9:56AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a "dead cat bounce" (down big yesterday but up big today) candidate
Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:34AM CDT
TherapeuticsMD has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why TherapeuticsMD Inc. Stock Grew Wings
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of TherapeuticsMD , a drug manufacturer...
Why TherapeuticsMD (TXMD) Stock Is Surging Today
at The Street - Tue Jul 08, 9:39AM CDT
TherapeuticsMD (TXMD) surged Tuesday after FBR Capital initiated coverage on the pharmaceutical company with an "outperform" rating and a $34 price target.
Tuesday’s Top Health Care Stories: Zogenix, Philips, Siemens, and TherapeuticsMD
Leo Sun, The Motley Fool - Motley Fool - Tue Jul 08, 7:57AM CDT
Let's take a quick look at four stocks -- Zogenix , Philips , Siemens , and TherapeuticsMD -- which could all loom large in health care headlines this Tuesday morning. Zogenix drops on an FDA priority review for Purdue's rival painkiller ...
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cmmr7/vaginal_atrophy) has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Foamix Ltd. - Pantarhei Bioscience BV - Hygeia Therapeutics, Inc. - EndoCeutics, Inc. - TherapeuticsMD Inc. - Peptonic medical AB For more information visit http://www.researchandmarkets.com/research/7c...al_atrophy
TherapeuticsMD to Present at 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:30PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) announced today that the Company will present at the 9th Annual JMP Securities Healthcare Conference taking place at the Westin New York Grand Central on June 24-25, 2014.
Analyst Scanner on Health Care Sector Equities -- Research on Vical, VCA Inc., TherapeuticsMD, and Theravance
PR Newswire - Mon Jun 16, 7:00AM CDT
The trading session on Friday, June 13, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,775.74, up 0.25% and the NASDAQ Composite closed at 4,310.65, up 0.30%. The S&P 500 finished the day 0.31% higher at 1,936.16. The gains were broad based as nine out of the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 688.44, down 0.02%, while the index has gained 2.46% in the previous one month. Investor-Edge has initiated coverage on the following equities: Vical Inc. (NASDAQ: VICL), VCA Inc. (NASDAQ: WOOF), TherapeuticsMD Inc. (NYSE MKT: TXMD) and Theravance Inc. (NASDAQ: THRX). Free technical research on VICL, WOOF, TXMD and THRX can be downloaded upon signing up at:
TherapeuticsMD Announces Webcast for Investor Day on June 16, 2014
Business Wire - Tue Jun 10, 6:04AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) a women's health care company, ("TherapeuticsMD" or the "Company" announced today that it will webcast its upcoming Investor Day on June 16, 2014 to be held at the InterContinental Barclay New York in New York City commencing promptly at 11:30 a.m. EDT to approximately 2:30 p.m.
TherapeuticsMD, Inc. Launches the First Daily Chewable Prescription Prenatal Vitamins with FOLMAX
Business Wire - Wed May 28, 6:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company" , a women's healthcare company and parent company of vitaMedMD, LLC ("vitaMedMD" and BocaGreenMD, Inc. ("BocaGreenMD" , announced today the availability of the newly reformulated vitaMedMD(R) branded prescription prenatal vitamin, vitaMedMD RediChew(TM) Rx, and the BocaGreenMD(R) generic prescription prenatal vitamin Prena1 Chew. vitaMedMD RediChew Rx and Prena1 Chew are small, vanilla flavored, chewable prenatal vitamin tablets that dissolve quickly and are taken once daily.
TherapeuticsMD Announces 2014 Investor Day
Business Wire - Tue May 27, 6:15AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today that it will host its 2014 Investor Day on Monday, June 16, 2014, beginning at 11:30 a.m. EDT at the InterContinental Barclay New York in New York City.
TherapeuticsMD to Hold Second Quarter 2014 Financial Results Conference Call and Webcast on August 6
Business Wire - Fri Aug 01, 6:00AM CDT
TherapeuticsMD (NYSE MKT:TXMD), a women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss its second quarter financial and business results Wednesday, August 6. The conference call and webcast will take place at 4:30 p.m. EDT and will be hosted by Robert Finizio, Chief Executive Officer, and Dan Cartwright, Chief Financial Officer.
TherapeuticsMD plans to issue USD40m shares in public offering
M2 - Wed Jul 30, 6:37AM CDT
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) said on Tuesday that it intends to start its public offering of USD40m shares of its common stock.
TherapeuticsMD Announces Pricing of Offering of Common Stock
Business Wire - Wed Jul 30, 6:01AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the "Company"
announced today the pricing of an underwritten public offering of approximately 8.6 million shares of its common stock, offered at a price of $4.67 per share. The gross proceeds to the Company from this offering are expected to be approximately $40.0 million, before deducting underwriting discounts, commissions and other estimated offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 1.3 million additional shares of its common stock. The offering is expected to close on or about August 4, 2014, subject to the satisfaction of customary closing conditions. TherapeuticsMD Announces $40 Million Offering of Common Stock
Business Wire - Tue Jul 29, 3:13PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company"
today announced the launch of an underwritten public offering of $40 million of shares of its common stock. All of the shares in the offering are to be sold by the Company. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional $6 million of shares of its common stock. Technical Coverage on Pharma Stocks -- GlaxoSmithKline, TherapeuticsMD, AstraZeneca, Zogenix, and Novartis
PR Newswire - Tue Jul 22, 8:10AM CDT
On Monday, July 21, 2014, the NASDAQ Composite ended at 4,424.70, down 0.17%, the Dow Jones Industrial Average declined 0.28%, to finish the day at 17,051.73, and the S&P 500 closed at 1,973.63, down 0.23%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 707.91, down 0.39%, while the index has advanced 6.22% in the previous three months. Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), TherapeuticsMD Inc. (NYSE MKT: TXMD), AstraZeneca PLC (NYSE: AZN), Zogenix Inc. (NASDAQ: ZGNX), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at:
TherapeuticsMD Investor Update; BrokerBank Securities, Inc. Offers Insight on Long-Term Uncertainty Amid Short-Term Catalysts
PR Newswire - Tue Jul 15, 1:30PM CDT
According to BCC Research, the global market for women's health therapeutics is expected to reach $22.5 billion in 2018. Due to a variety of factors, such as an aging worldwide population, an increasing awareness among patients and physicians, the introduction of new therapies into the market, and the overall disease pattern and treatment differences between men and women, this market is expected to grow at a CAGR of 3.5% over the next five years.
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Jul 13, 6:30AM CDT
It was a rough week on Wall Street, with the market moving lower, but there were plenty of stocks still moving higher. Let's take a closer look at five of this past week's biggest scorchers. Company July 11 Weekly Gain ...
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD)
at The Street - Thu Jul 10, 9:56AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a "dead cat bounce" (down big yesterday but up big today) candidate
Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:34AM CDT
TherapeuticsMD has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
Today's 3 Most Volatile Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:05PM CDT
Biotechnology stocks are never short on volatility and today was no different as markets turned lower and biotech stocks were particularly hard hit. The Nasdaq Biotechnology Index ETF dropped more than 2% as investors embraced safety and avoided...
Why TherapeuticsMD Inc. Stock Grew Wings
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of TherapeuticsMD , a drug manufacturer...
Why TherapeuticsMD (TXMD) Stock Is Surging Today
at The Street - Tue Jul 08, 9:39AM CDT
TherapeuticsMD (TXMD) surged Tuesday after FBR Capital initiated coverage on the pharmaceutical company with an "outperform" rating and a $34 price target.
Tuesday’s Top Health Care Stories: Zogenix, Philips, Siemens, and TherapeuticsMD
Leo Sun, The Motley Fool - Motley Fool - Tue Jul 08, 7:57AM CDT
Let's take a quick look at four stocks -- Zogenix , Philips , Siemens , and TherapeuticsMD -- which could all loom large in health care headlines this Tuesday morning. Zogenix drops on an FDA priority review for Purdue's rival painkiller ...
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cmmr7/vaginal_atrophy) has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Foamix Ltd. - Pantarhei Bioscience BV - Hygeia Therapeutics, Inc. - EndoCeutics, Inc. - TherapeuticsMD Inc. - Peptonic medical AB For more information visit http://www.researchandmarkets.com/research/7c...al_atrophy
TherapeuticsMD to Present at 9th Annual JMP Securities Healthcare Conference
Business Wire - Tue Jun 17, 3:30PM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) announced today that the Company will present at the 9th Annual JMP Securities Healthcare Conference taking place at the Westin New York Grand Central on June 24-25, 2014.
Analyst Scanner on Health Care Sector Equities -- Research on Vical, VCA Inc., TherapeuticsMD, and Theravance
PR Newswire - Mon Jun 16, 7:00AM CDT
The trading session on Friday, June 13, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,775.74, up 0.25% and the NASDAQ Composite closed at 4,310.65, up 0.30%. The S&P 500 finished the day 0.31% higher at 1,936.16. The gains were broad based as nine out of the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 688.44, down 0.02%, while the index has gained 2.46% in the previous one month. Investor-Edge has initiated coverage on the following equities: Vical Inc. (NASDAQ: VICL), VCA Inc. (NASDAQ: WOOF), TherapeuticsMD Inc. (NYSE MKT: TXMD) and Theravance Inc. (NASDAQ: THRX). Free technical research on VICL, WOOF, TXMD and THRX can be downloaded upon signing up at:
TherapeuticsMD Announces Webcast for Investor Day on June 16, 2014
Business Wire - Tue Jun 10, 6:04AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD) a women's health care company, ("TherapeuticsMD" or the "Company"
announced today that it will webcast its upcoming Investor Day on June 16, 2014 to be held at the InterContinental Barclay New York in New York City commencing promptly at 11:30 a.m. EDT to approximately 2:30 p.m. TherapeuticsMD, Inc. Launches the First Daily Chewable Prescription Prenatal Vitamins with FOLMAX
Business Wire - Wed May 28, 6:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) ("TherapeuticsMD" or the "Company"
, a women's healthcare company and parent company of vitaMedMD, LLC ("vitaMedMD" and BocaGreenMD, Inc. ("BocaGreenMD" , announced today the availability of the newly reformulated vitaMedMD(R) branded prescription prenatal vitamin, vitaMedMD RediChew(TM) Rx, and the BocaGreenMD(R) generic prescription prenatal vitamin Prena1 Chew. vitaMedMD RediChew Rx and Prena1 Chew are small, vanilla flavored, chewable prenatal vitamin tablets that dissolve quickly and are taken once daily. TherapeuticsMD Announces 2014 Investor Day
Business Wire - Tue May 27, 6:15AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today that it will host its 2014 Investor Day on Monday, June 16, 2014, beginning at 11:30 a.m. EDT at the InterContinental Barclay New York in New York City.
